aap 2009: Without one-time effects sales growth of 13% in the first quarter

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

aap Implantate AG, a medical technology company listed on the
Frankfurt Stock Exchange in the Prime Standard segment, achieved in
the first quarter of the financial year 2009 - according to
preliminary figures - sales of EUR 8.4 million (+5% to first quarter
2008).

Both periods contain one-time effects. In the beginning of the
previous year, within an initial order from a global partner, we
registered revenues to the amount of EUR 1.0 million mainly for an
initial stock of instruments. In March 2009 we were able to sell a
product that does not belong anymore to the core business in the
amount of EUR 0.5 million. Without the consideration of these not
re-occurring revenues, aap realized a sales growth of 13%.

Within the cost reduction program, which was initialized at the end
of the previous financial year, first measures such as staff
reduction, closing of a site and prioritization of the research &
development projects were carried out in the first quarter. These
measures will show first effects on the company's performance during
the second half of the financial year, a complete impact will occur
in 2010.

Besides the capital increase of EUR 1,267,357 placed in March and the
financing commitment of a shareholder of EUR 2 million, aap was able
to achieve another contribution to securing the company's financing
by significantly reducing the terms of payments with major customers.

As a result of the revision of the separating strategy by business
segments, the development of the company under one roof and the
change of the management structure, the sales figures of the
financial year 2009 will not be published anymore with break downs
into the business segments Biomaterials and Trauma & Ortho.

The publication of the full report for the first quarter of 2009 is
scheduled for May 13, 2009.
_

aap is a medical technology company that develops, manufactures and
markets biomaterials and implants for trauma and orthopaedics. Its
product portfolio includes bone cements, bone graft substitutes,
antibiotic carriers, and implants for fracture healing and joint
replacement. In addition to its Berlin headquarters the company has
locations in Dieburg and Obernburg near Frankfurt am Main as well as
at Nijmegen in the Netherlands. aap Implantate AG has been listed in
the Prime Standard segment at the Frankfurt stock exchange since May
16, 2003.

Please address any queries to:
aap Implantate AG, Nanette Hüdepohl, Head of Corporate
Communications, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de

For further information about aap bio implants, visit
www.aap-bioimplants.com

--- End of Message ---

aap Implantate AG
Lorenzweg 5 Berlin Germany

WKN: 506660; ISIN:
DE0005066609; Index: CDAX, Prime All Share, TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter
Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.